FDA
-
-
-
-
-
-
-
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
-
-
-
-
-
-
-
Innoviva (INVA): FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
-
-
-
-
-
-
-
Armata Pharma (ARMP) announces secure credit agreement of $10 million with Innoviva
-
-
-
-
-
-
-
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
-
-
-
-
-
-
-
Innoviva (INVA) Announces Publication of Results from Phase 3 ATTACK Trial
-
-
-
-
-
-
-
Innoviva (INVA) Shares Halted Ahead of FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam
-
-
-
-
-
-
-
Innoviva (INVA) Completes Entasis Acquisition
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

